These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 17697543

  • 21. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
    Liu YX, Fan DM, Xiong DS, Xu YF, Shao XF, Xu YS, Peng H, Yang M, Qin L, Zhu ZP, Yang CZ.
    Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
    [Abstract] [Full Text] [Related]

  • 22. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
    Cervantes F, Miller JS, McGlave PB.
    Med Clin (Barc); 1995 Jun 10; 105(2):50-3. PubMed ID: 7603094
    [Abstract] [Full Text] [Related]

  • 23. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Jun 10; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 24. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 10; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 25. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Jul 10; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 26. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG.
    Exp Hematol; 2005 Apr 10; 33(4):452-9. PubMed ID: 15781336
    [Abstract] [Full Text] [Related]

  • 27. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F, Basse PH, Hokland M.
    Nat Immun; 2005 Apr 10; 15(2-3):134-46. PubMed ID: 9162263
    [Abstract] [Full Text] [Related]

  • 28. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.
    Cancer Sci; 2009 Jan 10; 100(1):54-61. PubMed ID: 19038008
    [Abstract] [Full Text] [Related]

  • 29. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K, Varalakshmi C, Khar A.
    Cytokines Cell Mol Ther; 1997 Mar 10; 3(1):51-8. PubMed ID: 9287244
    [Abstract] [Full Text] [Related]

  • 30. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

  • 31. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 32. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 33. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Jan 01; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 34. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z, Freedman MS.
    Clin Immunol; 2008 Aug 01; 128(2):219-27. PubMed ID: 18501678
    [Abstract] [Full Text] [Related]

  • 35. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.
    Cancer Res; 2004 Jul 01; 64(13):4664-9. PubMed ID: 15231679
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 37. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
    García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, Panizo A, Giraldo P, Rodríguez-Calvillo M, Grande C, Pena E, Olave M, Panizo C, Inogés S.
    Immunol Res; 2016 Apr 15; 64(2):548-57. PubMed ID: 26659089
    [Abstract] [Full Text] [Related]

  • 38. Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells.
    Lin SJ, Yang MH, Chao HC, Kuo ML, Huang JL.
    Pediatr Allergy Immunol; 2000 Aug 15; 11(3):168-74. PubMed ID: 10981526
    [Abstract] [Full Text] [Related]

  • 39. Characterization of lymphokine-activated killer cells from peripheral blood and lymph nodes of non-Hodgkin's lymphoma patients.
    Nadkarni JJ, Jhaver KG, De AK, Soman CS, Nadkarni KS.
    Neoplasma; 1993 Aug 15; 40(1):15-20. PubMed ID: 8350943
    [Abstract] [Full Text] [Related]

  • 40. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
    Yan JS, Chen XY, Li WP, Yang Y, Song ZL.
    Ai Zheng; 2009 Feb 15; 28(2):181-3. PubMed ID: 19550134
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.